SCHEMBL4393928

SCHEMBL4393928

N#Cc1ccc(-c2ccc(/C=C3\SC(=S)N(CCc4ccccc4)C3=O)o2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 1.00
CREBBP Q92793 1/20 1.00
HIF1AN Q9NWT6 1/20 0.57
STAT3 P40763 1/20 0.56
POLB P06746 3/20 0.56
ALDH1A1 P00352 3/20 0.56
MAPT P10636 3/20 0.56
LMNA P02545 2/20 0.56
RAB9A P51151 2/20 0.56
MAP3K5 Q99683 4/20 0.55
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
MCL1 Q07820 3/20 0.54
TDP1 Q9NUW8 2/20 0.54
RECQL P46063 2/20 0.54
EIF4E P06730 1/20 0.54
EIF4G1 Q04637 1/20 0.54
THRB P10828 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
PKM P14618 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4393931 1.00 EP300 (1.00) EP300CREBBPHIF1ANSTAT3POLB
SCHEMBL14025836 1.00 EP300 (1.00) EP300CREBBPHIF1ANSTAT3POLB
SCHEMBL14045772 0.91 EP300 (0.83) EP300CREBBPHIF1ANSTAT3POLB
SCHEMBL4394198 0.90 EP300 (0.82) EP300CREBBPHIF1ANSTAT3POLB
SCHEMBL4408844 0.90 EP300 (0.82) EP300CREBBPHIF1ANSTAT3POLB
SCHEMBL14860230 0.90 EP300 (0.81) EP300CREBBPHIF1ANSTAT3POLB
SCHEMBL14860228 0.90 EP300 (0.81) EP300CREBBPHIF1ANSTAT3POLB
SCHEMBL15827142 0.90 EP300 (0.81) EP300CREBBPHIF1ANSTAT3POLB
SCHEMBL3897810 0.87 EP300 (0.78) EP300CREBBPHIF1ANSTAT3POLB
SCHEMBL3897813 0.87 EP300 (0.78) EP300CREBBPHIF1ANSTAT3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1830848-B1 USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS CELL THERAPEUTICS EUROPE SRL (IT) 2009-12-16 EP claimed
EP-1830848-B1 USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS CELL THERAPEUTICS EUROPE SRL (IT) 2009-12-16 EP disclosed
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US disclosed
EP-1830848-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS Cell Therapeutics Europe S.R.L. (IT) 2007-09-12 EP disclosed
WO-2006066846-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS CELL THERAPEUTICS EUROPE S.R.L. (IT) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents EP300, HIF1A, HIF1AN EP300 1/4885CREBBP 10/4885HIF1AN 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.